Cannabis Science Update #3

Nice questions, Really, it all depends on what "your" intentions are for the Company. You can clearly see the future growth and outstanding medical drug development progress we have made. This is why we are here in the first place.

Nice questions, Really, it all depends on what "your" intentions are for the Company. You can clearly see the future growth and outstanding medical drug development progress we have made. This is why we are here in the first place.

You can clearly see the CBIS-EDP opportunities we are making available to the general public based on the progress the Company has made over the last few years ending up straight into Harvard. You can clearly see the progress in our CBIS -EDP and how it is actually taking off Worldwide. The CBIS -EDP is covering so many different industries that the money making economic changing opportunities we all have in that program is massive.

We as stated in the news release are in the middle of a very painful growth transition. We are negotiating and structuring a few very large financings and a new stock market liquidity path, it's already underway and it's all based on the success and growth we are clearly in the middle of. We realize the choices to succeed in our operations was the right one.

Also as stated in the news release, we are now paying the price for the choices made to attain that growth and success. I think we will all do very well.

Again, it depends on what your intentions are. Are you here to help or hinder ?? Only you really know that. We know why we are here. Killing cancer and going after a number of other nasty ailment targets so aggressively while we are educating and trying to help create jobs worldwide through our CBIS - EDP.

That's why we are here, we are gaining momentum everyday. So no matter what happens, it is a profound thing we are a part of right now and making history in unchartered territory in so many areas, we are all a part of that.

We can all stand up tall and be Proud to say we helped move this ball and come down to Harvard or watch the Harvard GHC Summit videos for the last three years and see for yourself and actually take part. That's why we are here.

I'm quite positive that once we complete the operational expansions, and perhaps even before we start trading again with a new stock symbol there will be people who will have the proper paperwork that will probably want to buy all of your shares. I'm quite certain we will all do very well regardless.

Again, we will be updating everyone here step by step with our progress. We designing some sort of timeline tracking system that updates so the questions can be answered in one spot and everyone can have instant access to the real time information tracking our drug development progress and how to purchase new product releases, our CBIS-EDP operations, financings, acquisitions, partnerships and trading status. Will take a minute, but we get the job done.

This chapter has just begun. However, as you can see our Journey is well underway the ups and the downs, the failures, and the successes. So yeah we think it's worth it.

Talk soon.


Cannabis Science Update #2

Thanks to everyone for your continued support and joining iCannabinoid for updates and current information!

I've been updating this info for now until we launch our proper information flow.
I’m excited, this is going to get real good!

We haven't even released the full CBIS-EDP website yet!

The News Release simply states:

"All Cannabis Science shareholders and their shareholdings will remain intact under the same name and entity, Cannabis Science Inc., a Nevada Corporation.

All Cannabis Science shareholders of record as of the last day trading whether individuals or entities will be eligible for the first rights IPO offering and shareholder loyalty gifts; all other new shareholders will be officially closed-out once the transition to private company status has occurred."

*** This means all your shares will stay intact when we go “Private”, you will receive the loyalty shareholder gift, and when we do an IPO you will have the first rights to purchase more. I think we might have a different valuation by then.

Moving forward we will be posting step by step updates here on iCannabinoid.

Based on the success we have been building; I think we will all do very well!

Talk soon.


Cannabis Science Update #1

Just Released !!! New Era !!! New Growth !!! New Beginnings !!!

Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth

Irvine, CA - (NewMediaWire) - October 21, 2019 - Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has agreed to go private under sanctions by the U.S. Securities and Exchange Commission (“SEC”). All Cannabis Science shareholders and their shareholdings will remain intact under the same name and entity, Cannabis Science Inc., a Nevada Corporation. Cannabis Science shares will no longer be quoted or traded on any stock market exchange.

Once the private corporation status takes effect the Company’s President will begin the steps to file a Dutch auction IPO targeting $25,000,000 USD or more with all current shareholders intact with completed financials, first rights IPO offerings for current shareholders, new shareholder IPO offerings, and a new company trading symbol. All Cannabis Science shareholders of record as of the last day trading whether individuals or entities will be eligible for the first rights IPO offering and shareholder loyalty gifts; all other new shareholders will be officially closed-out once the transition to private company status has occurred.

Cannabis Science Inc. President and CEO Raymond C. Dabney stated, “This is probably one of the most exciting times for Cannabis Science in terms of the rate of our growth and the number of international positive cash flow projects the company is entering into right now through its Economic Development Program (CBIS-EDP). We are certainly transitioning into a very large multi-national conglomerate real fast and we must guide this massive battleship home with ease and control. As we transition into ‘Step (2)’ of this growth, the associated growing pains we are experiencing right now have certainly shaken up and taken a toll on the company’s operations and our complete line of auditing and fully reporting capabilities. After extensive communications with the SEC regarding our business growth and how best to manage it with the SEC’s reporting requirements and information-flow constraints, I have come to realize that this is the best course of action right now so we can focus on growing our business and becoming cash-flow positive. With that in mind, I agree with the SEC on this one; it is time to make the required moves to protect our successful business growth and as a result protect our shareholders’ value.

“All shareholders will be able to register on to get live access to current financial information, share trading status, new acquisitions, partnerships and opportunities, news releases, progress reports, presentations, new financings, first rights IPO opportunities and shareholder loyalty gifts. As well, inside of the iCannabinoid website we will be offering businesses, students, and entrepreneurs everywhere full access to our university economic development plan (CBIS-EDP) categorized by Countries, Regions, Industries, Educational, Leadership, and Partnership Opportunities. We will be accepting pre-registrations for our hybrid-University courses and accepting bid tenders for partnerships, operations and expansions in the many different industries we are targeting for the CBIS-EDP.

“Our strong partnership opportunities is the main reason our CBIS-EDP is seeing such success; for the past ten years we have built up a robust pipeline of economic growth opportunities worldwide centered around education, job creation, drug development, agriculture, high-tech, banking & finance, communications, real estate & construction, medical services, security, TV & media, mining & natural resources, political & government relations, manufacturing, teaching, sales & marketing, retail services, warehousing & distribution, and entrepreneurial business incubators for those who wish to own their own businesses and create jobs anywhere, even in your own community, in virtually any industry worldwide.

“These new initiatives have created significant reporting requirements for the Company in multiple jurisdictions worldwide, while Cannabis Science is simultaneously investing in the necessary infrastructure to successfully execute these exciting initiatives. By going private, the Company will have the opportunity to stabilize its growth and put the necessary systems in place to ensure that Cannabis Science successfully maintains its growth over the long-term, and over the short-term the Company will be able to move at the speed of light. Cannabis Science’s CEO will be empowered to move much faster to structure new partnerships and acquisitions to add value and liquidity to the Company’s shares through partnerships and acquisitions with new private and public companies operating on exchanges worldwide, to take advantage of and better align with Cannabis Science global operations.

“Over the last several years, Cannabis Science has invested heavily in its drug development, education, and economic development initiatives. As for drug development, Cannabis Science has a tremendous pipeline of potential critical ailment products and is planning for clinical trials early next year. Cannabis Science also has a number of products currently available and under development for the state and over-the-counter (OTC) markets. Similarly, Cannabis Science has made considerable progress with its education and economic development programs internationally.

"This is what it’s all about; the CBIS-EDP is real, down to earth, accessible economic development plans, industry specific enhancements, job creation, education, food and drug distribution. We have made this program available to everyone in virtually any demographic worldwide that needs economic industry stimulation or cost-effective drug development for medical issues, restructure for economic growth, education, and jobs for the people. We just made the World Series, and its game on! Looking forward to seeing you all live on iCannabinoid!” Concludes Mr. Dabney.

About Cannabis Science, Inc.

Cannabis Science is the first publicly-traded cannabinoid company on the market, and is a leader in the research and development of cannabinoid-based medicines and associated delivery technologies. Cannabis Science and its research collaborators are currently conducting pre-clinical research on cannabinoid-based medicines with plans to transition to clinical trials on a number of products this year. Targeted indications include Lung Cancer, Pancreatic Cancer, Chronic Prostatitis, Obsessive Compulsive Disorder (OCD), Oro-bucco-lingual Dyskinesias, Oxidative Stress, Psychosis, and Post Traumatic Stress Disorder (PTSD). CBIS is also currently in negotiations to license the Company’s U.S. patent number 9,763,991 for the Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, including Sleep Disorders. CBIS recently announced its drug-development pipeline ( and the transition into clinical trials as well as other major company initiatives.

Cannabis Science takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, neurological conditions, and other indications as identified previously. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information

Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1-310-650-3788

Connect, Learn, and Share!

For Live Chat and Live Updates.

Page 4 of 4

Cannabis Science Economic Development Program

Cannabis Science Economic Development Plan

Cannabis Science Share Structure Updates

CBIS Share Structure Updates

Transfer Agent

Securities Transfer Corp.

STC is regulated by the Securities and Exchange Commission

2901 N Dallas Parkway
Suite 380
Plano, Texas 75093
(469) 633-0101

Become an iCannabinoid Ambassador


Observational Studies


Activity Stream…

Loading content, please wait.
Rodrigo Soltero I havent seen any movement on my shares.. what happened with the exchange? 3 days ago
Sam Salem Hi Raymond, can you please advise as to how many full time employees are at the company currently?
Thank you
2 days ago
Darewood Steinhoff I appreciate this update, but it doesn't really provide a clear roadmap on what is happening with the shares that are curerntly delisted from... Show more 20 hours 22 minutes ago

This is the "Price for Not reading" anything.

Good Morning Guys!
Hope Everyone is doing well out there!

We have really been having some Great calls...
Show more

Bryce How do we get on the email distribution list? I got a couple emails a year or two ago but haven’t been receiving any in at least a year. 2 days ago
Philip Rigg Good question. I have been with CBIS for over 2 years and have NEVER gotten an e-mail from anyone connected with Omnicanna. 2 days ago
MICHAEL WALKER Same here have owned the stock for years and even sent an email requesting information investing in the new adventure. Yet to receive an email yesterday